中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study

文献类型：期刊论文

作者Wu, Xiaohua3; Zhu, Jianqing4; Wang, Jing5; Lin, Zhongqiu6; Yin, Rutie7; Sun, Wei8; Zhou, Qi9,10,11; Zhang, Songling12; Wang, Danbo13; Shi, Hong14
刊名CLINICAL CANCER RESEARCH
出版日期2022-02-15
卷号28
ISSN号1078-0432
DOI10.1158/1078-0432.CCR-21-1186
通讯作者Wu, Xiaohua(wu.xh@fudan.edu.cn)
英文摘要Purpose: Phase I results of this phase I/II study showed that pamiparib 60 mg twice a day had antitumor activity and an acceptable safety profile in Chinese patients with advanced cancer, including epithelial ovarian cancer. Patients and Methods: This open-label phase II study was con-ducted in China and enrolled adult (>= 18 years) patients with plat-inum-sensitive ovarian cancer (PSOC; disease progression occurring >= 6 months after last platinum treatment) or platinum-resistant ovarian cancer (PROC; disease progression occurring <6 months after last platinum treatment). Eligible patients had known or sus-pected deleterious germline BRCA mutation (gBRCA(mut)) and had previously received >= 2 lines of therapy. Pamiparib 60 mg orally twice day was administered until disease progression, toxicity, or patient withdrawal. The primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per RECIST version 1.1. Results: In the total patient population (N = 113; PSOC, n = 90; PROC, n = 23), median age was 54 years (range, 34-79) and 25.6% of patients received >= 4 prior systemic chemotherapy lines. Median study follow-up was 12.2 months (range, 0.2-21.5). Eighty-two patients with PSOC and 19 patients with PROC were evaluable for efficacy. In patients with PSOC, 8 achieved a complete response (CR) and 45 achieved a partial response (PR); ORR was 64.6% [95% confidence interval (CI), 53.3-74.9]. In patients with PROC, 6 achieved a PR; ORR was 31.6% (95% CI, 12.6-56.6). Frequently reported grade >= 3 adverse events were hematologic toxicities, including anemia and decreased neutro-phil count. Conclusions: Pamiparib 60 mg twice a day showed antitumor activity with durable responses in patients with PSOC or PROC with gBRCA(mut), and had a manageable safety profile.
WOS关键词SELECTIVE PARP INHIBITOR ; ANTITUMOR-ACTIVITY ; BRCA2 MUTATION ; OLAPARIB ; SAFETY ; CARCINOMA ; RUCAPARIB ; POTENT
资助项目BeiGene, Ltd.
WOS研究方向Oncology
语种英语
出版者AMER ASSOC CANCER RESEARCH
WOS记录号WOS:000756668200001
资助机构BeiGene, Ltd.
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/127909]  
专题中国科学院合肥物质科学研究院
通讯作者Wu, Xiaohua
作者单位1.BeiGene USA Inc, Dept Clin Pharmacol, San Mateo, CA USA
2.Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, Jinan, Peoples R China
3.Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
4.Univ Chinese Acad Sci, Dept Gynecol Oncol, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
5.Cent South Univ, Hunan Canc Hosp, Dept Gynecol & Oncol, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China
6.Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gynecol Oncol, Guangzhou, Peoples R China
7.Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, West China Hosp 2, Dept Obstet & Gynecol,Minist Educ, Chengdu, Peoples R China
8.Anhui Prov Canc Hosp, Affiliated Hosp USTC 1, Dept Gynecol Oncol, Hefei, Peoples R China
9.Chongqing Univ, Dept Gynecol Oncol, Canc Hosp, Chongqing, Peoples R China
10.Chongqing Canc Inst, Chongqing, Peoples R China
推荐引用方式
GB/T 7714		 Wu, Xiaohua,Zhu, Jianqing,Wang, Jing,et al. Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study[J]. CLINICAL CANCER RESEARCH,2022,28.
APA Wu, Xiaohua.,Zhu, Jianqing.,Wang, Jing.,Lin, Zhongqiu.,Yin, Rutie.,...&Kong, Beihua.(2022).Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.CLINICAL CANCER RESEARCH,28.
MLA Wu, Xiaohua,et al."Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study".CLINICAL CANCER RESEARCH 28(2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。